WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

Core Insights - WuXi Biologics has received the AAA ESG rating from MSCI for the third consecutive year, highlighting its commitment to sustainability and strong ESG performance [1][2]. Company Performance - The AAA rating places WuXi Biologics among an elite group of companies recognized for outstanding ESG performance, particularly in climate change, product safety, human capital development, and corporate governance [2]. - The company has been actively engaged with the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, aligning its efforts with the United Nations Sustainable Development Goals [4]. Recognition and Awards - WuXi Biologics has received multiple accolades for its sustainability efforts, including an EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices, and recognition as a top-rated company by Sustainalytics for five consecutive years [5]. - The company has also been rated as Prime by ISS ESG Corporate Rating and is a constituent of the FTSE4Good Index Series [5]. Operational Overview - WuXi Biologics employs over 12,000 skilled employees across various countries, including China, the United States, Ireland, Germany, and Singapore, providing efficient and cost-effective biologics solutions [8]. - As of June 30, 2025, the company is supporting 864 integrated client projects, with 24 in commercial manufacturing [8]. Commitment to Sustainability - The company views sustainability as a cornerstone of long-term business growth and continuously drives green technology innovations to offer advanced Green CRDMO solutions [9]. - WuXi Biologics collaborates with stakeholders to foster positive social and environmental impacts, promoting responsible practices throughout the value chain [9].